Blue Horizon appoints Manu Gupta to Board of Directors

Blue Horizon

Zurich, 1 December 2021 – Blue Horizon, a pure-play impact investor accelerating the transition to a new Sustainable Food System, welcomes Manu Gupta, a leader in US and European venture capital, to its Board of Directors.

The appointment of Manu Gupta to the Board of Directors further bolsters the leadership of Blue Horizon with additional strategic counsel from a leader in venture capital investment with a track record identifying early-stage opportunities primed for growth.

Manu joins a Board that has overseen the rapid expansion of Blue Horizon in the last 6 years since founding, on a mission to accelerate the global transition to a new sustainable food system while delivering outstanding returns for investors and the planet.

The news follows significant business developments of the asset manager which recently appointed a General Counsel, a new Partner as well as two Directors to the investment team. The investment team of 9 now consists of 67% women with 28 Blue Horizon employees worldwide. Manu brings a wealth of experience and knowledge to the Board of Directors at an inflection point of new investment opportunities in sustainable food and agriculture innovation, which Blue Horizon aims to capture amid increasing interest from institutional investors and multibillion-dollar funds in a sustainable future of food.

Manu has been investing in tech for more than 12 years across the US, Europe, and Asia. Today he is best known as founder of Blue Lion, a venture capital firm that invests in multi-stage technology companies. Manu is also a founding member and ex-Partner of Lakestar, one of Europe’s largest tech venture funds. His investments and board memberships include Opendoor (IPO), SoFI (IPO), Robinhood (IPO), Maker Studios (M&A), Pipe, Forward Health, Figure Tech, Taulia, Aetion Health, Builder.ai, Even Health, Vested Finance, Casafari, Omio, to name a few.

Manu was previously an Executive Director and Head of European Internet coverage at Goldman Sachs, working across both the London and San Francisco offices. He started his career as a Product Manager at Oracle and software coder at Sun Microsystems. Manu graduated with honors in Electrical Engineering & Computer Science (EECS) from UC Berkeley and has an MBA from the University of Chicago. He has lived in San Francisco, Chicago, New York, Zurich and London.

Bjoern Witte, Managing Partner & CEO of Blue Horizon, said: We are very excited to announce that Manu has joined the Board of Directors as we continue to grow Blue Horizon’s deep bench of talent, drawing expertise from across disciplines that include venture capital, technology, and scientific research to cement our position as the leader in the transition to a new Sustainable Food SystemAs a well-renowned venture capitalist, Manu brings an invaluable perspective grounded in more than a decade of personal experience investing in early stage start-ups that have gone on to become global technology leaders which gives us another unique advantage to create value for investors and a sustainable future of food.

Manu Gupta, Member of the Board of Directors at Blue Horizon, said:“Blue Horizon invests at the forefront of an industry that will change the way all of us think about food. I am delighted to join such a high calibre board and actively help shape the bright future of this young company. Blue Horizon offers the possibility to participate in a market opportunity that offers outstanding returns for investors and the planet and I am very much looking forward to being an active part of this ecosystem.”

To date, Blue Horizon has raised funds of over $850 million and invested in 50+ companies with a focus on protein alternatives and food tech. Some of the firm’s most recent investments include Planted, an alternative protein start-up, Mosa Meat, which is developing tissue engineering technologies to mass produce affordable, cultured meat and dairy formulation and AgBiome, the leader in developing innovative products from the Earth’s microbial communities.

Media Release Blue Horizon appoints Manu Gupta to Board of Directors (PDF)

Categories: People

Jesse Väisänen appointed Investment Analyst for Tesi’s Growth and Industrial Investments team

Tesi

Jesse Väisänen

Jesse Väisänen has been appointed investment analyst for Tesi’s Growth and Industrial Investments team as of December 1st, 2021. Jesse is currently working as an investment analyst trainee at Tesi. Jesse holds an M.Sc. in Economics and Business Administration from Aalto University School of Business and he has majored in finance.

Congratulations, Jesse!

Tesi (Finnish Industry Investment Ltd) is a state-owned investment company that wants to raise Finland to the front ranks of transformative economic growth by investing in funds and directly in companies. We invest profitably and responsibly, hand-in-hand with co-investors, to create the world’s new success stories. Our investments under management total 2.1 billion euros. www.tesi.fi | @TesiFII

Categories: People

Cooper Consumer Health announces the appointment of Bart Meermans as CEO and the acquisition of Lashilé Beauty

CVC Capital Partners

The acquisition of Cooper Consumer Health by CVC Capital Partners Fund VII is completed

Cooper Consumer Health (“Cooper”) a leading European independent over-the-counter drug manufacturer and distributor, is pleased to announce the appointment of Bart Meermans as its new Chief Executive Officer and the agreement to acquire French consumer health food supplement business, Lashilé Beauty.

Bart Meermans has a wealth of industry experience having spent the last ten years at Reckitt Benckiser in a number of roles, most recently as Senior Vice President responsible for leading the company’s health businesses in Africa, Middle East, Turkey and Pakistan. Under his leadership the regions completed a significant digital transformation, which tripled online sales. Prior to this, Bart spent fifteen years in managerial roles at Omega Pharma and Procter & Gamble. Bart will succeed Bauke Rouwers, who will step down from his current CEO role, effective immediately.

Cooper has also agreed to acquire French nutraceutical company Lashilé Beauty, the market-leader in the fast-growing gummy dietary supplement category in France. The business fits well the bolt-on strategy of Cooper, with a complementary product portfolio with attractive underlying growth, a scalable business model that can be rolled-out internationally, and strong online and digital marketing know-how.

Yvan Vindevogel, Chairman of Cooper, added: “We are thrilled to be bringing Bart on board. His wealth of experience in the sector will be central to helping us accelerate Cooper’s ambitious growth plans. I also want to thank Bauke for his dedication in building the company during an extraordinary period over the last two years. We are tremendously excited about the future and in particular about our new partnership with Lashilé Beauty, a partnership which will be highly complementary to both businesses, helping us provide our customers with more ways to look after their health and wellbeing.”

Bart Meermans, incoming CEO of Cooper, said: “I am delighted to join the Cooper team and I look forward to working with my new colleagues as we embark on the journey of becoming a leading European Healthcare company. I believe that providing self-care, by empowering people to take better care of their health, is meaningful and inspirational, and equally unlocking a significant runway for growth.”

On the acquisition of Cooper, CVC partnered with Vemedia founder Yvan Vindevogel, specialised healthcare fund Avista Capital Partners, the management team, and Charterhouse which made a significant reinvestment in the company. The Lashilé Beauty founders will also become shareholders in Cooper. The entry into exclusive negotiations was initially announced earlier this year and the new shareholders are excited to support the company’s organic and acquisitive growth plans.

Categories: News People

Tags:

Gilde Healthcare portfolio company Noema Pharma expands its Board of Directors with the appointments of Catherine Mou…

GIlde Healthcare
November 9, 2021
Utrecht, The Netherlands & Basel, Switzerland
Utrecht, The Netherlands & Basel, Switzerland, November 9, 2021 – Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Catherine Moukheibir and Ilise Lombardo as independent members of the company’s Board of Directors. Ms. Moukheibir has extensive experience in finance, capital markets and life sciences, having held a number of senior executive and board-level positions in the biotech and pharmaceutical sectors. Dr Lombardo, MD is currently Chief Medical Officer at Kriya Therapeutics and has previously led clinical development and medical affairs programs with a focus on diseases of the nervous system. 

“I am very pleased to welcome Catherine and Ilise to the board of Noema Pharma. They are joining us at a pivotal time, while we are making significant progress in our clinical, structural and financial development,” said Luigi Costa, Chief Executive Officer of Noema Pharma. “Catherine and Ilise are highly respected executives in innovative life sciences companies with exceptional track records. Their considerable experience and knowledge will make them invaluable members of our board. We look forward to their advice, which will strengthen our Company’s leadership and support its mission to positively impact the lives of patients, as well as continuing to create shareholder value.”

The two new appointments further expand the Company’s board and follow the recent appointment of Jeffrey Jonas MD as the Chairman of the Board of Directors. Ms. Moukheibir and Dr. Lombardo join current board members Darren Carroll from Polaris Partners, Antoine Papiernik from Sofinnova Partners and Arthur Franken from Gilde Healthcare.

“I am thrilled to be part of Noema’s effort to develop groundbreaking therapies for the most debilitating symptoms in orphan conditions of the brain and central nervous system,” said Catherine Moukheibir, Board Member of Noema Pharma. “Last year’s successful Series A funding round has put the company in a strong financial position to advance its clinical mission and the company’s development to the next stage.”

“I am delighted to be joining Noema Pharma’s board and I’m looking forward to working with Noema’s dedicated and talented executive team,” said Ilise Lombardo MD, Board Member of Noema Pharma. “It is an exciting time for the Company, as it has recently initiated its first clinical trial in patients with Tourette syndrome and is planning to start two additional trials in the near future. These product candidates have the potential to offer new solutions for patients with debilitating conditions and I am thrilled to share my input into the various development efforts.”

About Catherine Moukheibir
Catherine Moukheibir currently serves on the Board of Directors at DNA Script, Asceneuron, Biotalys, CMR Surgical, Ironwood Pharmaceuticals and Orphazyme. She has previously held board memberships at Kymab, GenKyoTex, Cerenis, Zealand, Ablynx and Creabilis. Ms. Moukheibir was Chair and CEO of MedDay Pharmaceuticals and has also held senior executive positions at Innate Pharma, Movetis, and Zeltia Group. Before moving into the life sciences industry, Ms. Moukheibir worked in investment banking. She received an MBA and a Masters in Economics from Yale University.

About Ilise Lombardo
Ilise Lombardo is Chief Medical Officer at gene therapy company Kriya Therapeutics, where she leads the clinical and medical departments advancing a pipeline of gene therapy candidates across multiple therapeutic areas. Prior to joining Kriya, Dr. Lombardo was co-founder and Chief Medical Officer of epilepsy-focused company Arvelle Therapeutics. She has also held senior roles in clinical and medical development at Axovant Sciences, Forum Pharmaceuticals and Pfizer. She has a medical degree from Yale University, an M.Phil from the University of Cambridge and a bachelor’s degree from Brown University.

About Noema Pharma
Noema Pharma (www.noemapharma.com) is a Swiss-based company targeting orphan neurological disorders characterized by imbalanced neuronal networks. The company is developing four mid-clinical-stage therapeutic products in-licensed from Roche and with strong safety packages. Lead product NOE-101, an mGluR5 inhibitor, is Phase 2b-ready for two indications: persistent seizures in Tuberous Sclerosis Complex (TSC) and severe pain in Trigeminal Neuralgia (TN). NOE-105, a PDE10A inhibitor, is currently in Phase 2a investigated in patients with Tourette Syndrome. The Company is undertaking validation studies in undisclosed indications for two additional clinical-stage assets, NOE-109, an mGluR2/3 inhibitor, and NOE-115, a triple re-uptake inhibitor. Noema Pharma was founded with the leading venture capital firm Sofinnova Partners. Investors include Polaris Partners, Gilde Healthcare, Invus and Biomed Partners.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor with $1.8 billion under management across two fund strategies: Venture&Growth and Private Equity. The firm operates out of offices in Utrecht (The Netherlands), Frankfurt (Germany) and Cambridge (United States). Gilde Healthcare Venture&Growth invests in innovative companies active in (Bio)pharmaceuticals, Healthtech and Medtech. The portfolio of the Venture&Growth fund is balanced with fast growing life science companies from Europe and North America. For more information, please visit: www.gildehealthcare.com.

Contacts

Noema Pharma
Luigi Costa
Chief Executive Officer
info@noemapharma.com

Investors
LifeSci Advisors – Guillaume van Renterghem
gvanrenterghem@lifesciadvisors.com
+41 (0) 76 735 01 31

Media
LifeSci Advisors – Bernhard Schmid
bschmid@lifesciadvisors.com
+41 (0) 44 447 12 21

 

Categories: People

3i portfolio company Action announces appointment of Hajir Hajji to succeed Sander van der Laan as CEO

3I

The Board of Directors of Action announced today that Sander van der Laan will be stepping down as CEO of Action to be succeeded by Hajir Hajji, currently Commercial Director and member of the executive management team. The handover marks the next phase of development for Action, in which continued commitment to its customers and significant growth will be coupled with the further implementation of Action’s digital and sustainability strategy.

Sander van der Laan (53) joined Action as CEO in 2015. Under his leadership, Action has grown from €2 billion revenue with 655 stores in six markets to over €5 billion revenue and 1,869 stores in nine markets now. Sander very successfully led the delivery of the Action strategy also during the challenging Covid-19 period, during which Action and its employees demonstrated extraordinary resilience.

Simon Borrows, Chief Executive of 3i and Chairman of the Board of Action: “On behalf of 3i and Action’s Board I want to recognise and thank Sander for successfully leading the company. Action has continued its strong growth despite the uncertainties presented by the pandemic. He leaves the business performing strongly and on track to deliver its business plan. He has been a driven and committed colleague and I want to thank Sander for his leadership and wish him the very best.”

Sander van der Laan added: “It has been a great pleasure to lead such a great company and team. The passion and drive of our employees has been a source of inspiration for me. When I joined Action, my task was very clear: further strengthen the foundations of the company as the fastest growing non-food discounter in Europe and prepare the leadership of the company for the future. We will soon be opening our 2,000th store and I believe this is the right time for Hajir to take over from me. Hajir is Action. Her achievements across the business are unprecedented. And she is the right professional to lead the team and our operations into the next phase of growth and development. I want to thank Simon and all other members of the Board, my colleagues in the executive management team and all our employees who make Action such an amazing company, for their enormous support during my six years at the helm of Action.”

Hajir Hajji: through the ranks of Action

Hajir Hajji (41) joined Action 24 years ago as a store employee, then aged 17. Over the years she has successfully worked her way through the ranks of the organisation in a variety of management roles. Hajir was Director Store Operations for seven years, responsible for Action’s sales and international retail operations, including the opening of new stores and expansion to new markets. For the past three years Hajir worked as Commercial Director, responsible, amongst other things, for global buying, marketing, e-commerce and sustainability. Hajir has been a member of the executive management team since 2011.

The Action Board is delighted that Hajir will succeed Sander. Simon Borrows: “Hajir is a significant part of the Action DNA and the natural successor to Sander. Action is ready for the next phase of its growth agenda with an increased focus on digital and sustainable growth, two areas for which Hajir is currently responsible. Hajir has great retail expertise and is a strong leader. A long-standing Action executive and an advocate of the Action culture and values, she will bring both continuity and a new push for Action’s next phase of growth. I look forward to working with her and wish her success in her new role.”

Hajir Hajji: “Action is a great business with a very strong formula and a unique culture. As we move into a next phase of growth and development, I intend to continue building on our past achievements and explore with our 65,000 dedicated employees and our partners the opportunities ahead. I want to thank Sander for his contribution to the business during his time as CEO, our cooperation and for helping me to get accustomed to my new role. And I want to thank the Board for their confidence in me and the entire Action team.”

Hajir will formally become CEO of Action on 1 January 2022, while Sander will remain with the company until the end of March 2022 in order to ensure a smooth transition. The appointment of Hajir is subject to advice from Action’s works council.

Download this press release  

– Ends –

For further information, contact:

3i Group plc
Silvia Santoro
Investor enquiries
Tel: +44 20 7975 3285
Email: silvia.santoro@3i.com
Kathryn van der Kroft
Media enquiries
Tel: +44 20 7975 3021
Email: kathryn.vanderkroft@3i.com

 

About 3i Group

3i is a leading international investment manager focused on mid-market Private Equity and Infrastructure.  Our core investment markets are northern Europe and North America.

For further information, please visit: www.3i.com

About Action

Action is the fastest growing non-food discounter in Europe, offering an ever changing variety of c.6,000 products in almost 1,900 stores to more than 11 million customers every week. In addition, each week another eight million consumers visit the Action.com website. Action employs over 65,000 people in nine countries with over 130 different nationalities. While offering our constantly surprising assortment at the lowest prices, we continue to improve our products in terms of quality and sustainability. The business has responded well to the challenges posed by the pandemic and is on track to deliver on its growth plans for 2021 and beyond in all its markets. The promise of Action: Small prices. Big Smiles.

news-action-logo.jpg

Categories: People

DIF Capital Partners makes senior IR hire to cover North America

DIF

Continuing to build on the firm’s growing North American investor base and in anticipation of upcoming fundraisings initiatives, DIF Capital Partners (“DIF”) is excited to announce the expansion of its investor relations & business development team with a senior hire in North America.

Toms Lokmanis is joining as a Senior Director, based in Toronto, and will be responsible for covering the North American institutional market, including DIF’s existing investors and investment consulting firms. Toms brings over 12 years of industry experience. Prior to joining DIF, Toms worked at CBRE Caledon, now CBRE Investment Management (“CBRE”), out of the Toronto office, where he focused on growing the firm’s managed infrastructure and real estate strategies. Before CBRE he worked at Manulife Investment Management and Industrial Alliance in senior institutional sales roles. Toms is a CFA Charterholder and Chartered Alternative Investment Analyst (CAIA) and holds a B.A. Honours in Economics from McMaster University.

Allard Ruijs, Partner and Head of Investor Relations & Business Development: “I am very happy to welcome Toms to DIF Capital Partners. We believe he is a great first local hire for the IRBD team contributing his strong personal North American reputation, a relevant investor network as well as significant capital raising experience. Toms will lead in further developing DIF’s investor network and strengthening of the DIF brand positioning in North America.”

About DIF Capital Partners

DIF Capital Partners is a leading global independent fund manager, with more than €9.0 billion in assets under management across nine closed-end infrastructure funds and several co-investment vehicles. DIF Capital Partners invests in greenfield and operational infrastructure assets located primarily in Europe, the Americas, and Australasia through two complementary strategies:

  • Traditional DIF funds, of which DIF Infrastructure Fund VI is the latest vintage, target equity investments with long-term contracted or regulated income streams including public-private partnerships, concessions, utilities, and (renewable) energy projects.
  • DIF CIF funds, of which DIF CIF II is the latest vintage, target equity investments in small to mid-sized economic infrastructure assets in the telecom, energy, and transportation sectors.

DIF supports the goal of Net Zero greenhouse gas emissions by 2050, in-line with global efforts as a result of the Paris Agreement to have net zero emissions by 2050, or sooner.

DIF Capital Partners has a team of over 170 professionals, based in ten offices located in Amsterdam (Schiphol), Frankfurt, London, Luxembourg, Madrid, New York, Paris, Santiago, Sydney, and Toronto. For more information please visit www.dif.eu.

Contact:
Allard Ruijs, IR & BD
Email: a.ruijs@dif.eu

Categories: People

Martin Welna joins Adelis as new Partner based in Denmark

Adelis Equity

We are pleased to announce that Martin Welna will join Adelis as a new Partner from October 1st 2021.

Martin brings more than 15 years of professional experience from senior positions in private equity, investment banking, as well as an operational background.

The recruitment of Martin Welna is part of a carefully planned succession process where former Adelis Partner Steffen Thomsen has chosen to move into a Senior Advisor role.

“We are very pleased that Martin is joining the Adelis team. He has a strong investment track record in private equity coupled with a successful operational career. Denmark is a very important market for Adelis and our team has made several successful investments there over the past eight years. We are excited about adding Martin’s capabilities to help us continue to build the leading lower mid-market private equity firm in Denmark and the Nordics”, says Jan Åkesson, Co-Managing Partner at Adelis.

“Having spent more than 20 great years in private equity, including the better part of a decade with Adelis, I am looking forward to having more time for my other interests, while at the same time supporting Adelis in Denmark in my new role as a Senior Adviser”, says Steffen Thomsen.

Martin will be based in Adelis’ new office location in Copenhagen.

For enquiries please contact:

Martin Welna, + 45 21 99 67 57

Steffen Thomsen, + 45 40 28 34 09

Jan Åkesson, + 46 70 353 11 11

Categories: People

Blackstone Announces Appointment of Emily Yoder as Senior Managing Director, Strategic Relationships

Blackstone

New York, New York – October 13, 2021 – Blackstone today announced the appointment of Emily Yoder as Senior Managing Director, Strategic Relationship Management. She will serve as a primary interface with Blackstone’s banking and other financial services partners. In this newly created role, Ms. Yoder will be responsible for delivering a firm-wide approach to relationship management.

Commenting on the announcement, Vik Sawhney, Chief Administrative Officer and Global Head of Institutional Client Solutions said: “We’ve known Emily for many years, and I’m very excited to welcome her to the Blackstone team. Her skills will help us deepen our relationships with key financial partners as we continue to rapidly expand into new verticals.”

Emily Yoder commented: “I’ve grown to know Blackstone during my tenure in the financial services industry and am thrilled to be joining the firm during a time of rapid growth. I look forward to partnering with the leadership team to deepen our banking relationships and provide capital solutions as the business expands.”

Before joining Blackstone in 2021, Ms. Yoder worked at JPMorgan as a Managing Director in their Senior Relationship Management team, focusing on hedge funds and alternative asset managers. Ms. Yoder started her career in trading for JPMorgan, and was a founding member of the Emerging Markets Eurobond Trading team at JPMorgan in London. Ms. Yoder was the primary risk taker focusing on FX, Cross-Currency Swaps, and Local Market government bonds in CEEMEA & Latin America. Ms. Yoder graduated from Rice University in Houston, Texas with a B.A. in Mathematical Economic Analysis and Latin America Studies.

About Blackstone
Blackstone is the world’s largest alternative asset manager. We seek to create positive economic impact and long-term value for our investors, the companies we invest in, and the communities in which we work. We do this by using extraordinary people and flexible capital to help companies solve problems. Our $684 billion in assets under management include investment vehicles focused on private equity, real estate, public debt and equity, life sciences, growth equity, opportunistic, non-investment grade credit, real assets and secondary funds, all on a global basis. Further information is available at www.blackstone.com. Follow Blackstone on Twitter @Blackstone.

Contact
Kate Holderness
Kate.Holderness@blackstone.com
646-482-8774

Categories: People

Monika Vnuk and Matt Lane join Blackstone Life Sciences as Managing Directors

Blackstone

Cambridge, MA – October 13, 2021 – Blackstone Life Sciences (“BXLS”), Blackstone’s life sciences business, announced today that Dr. Monika Vnuk and Matt Lane have joined BXLS as Managing Directors in the firm’s Cambridge office. Dr. Vnuk joins from Pfizer, where she served as Vice President of Worldwide Business Development, having recently led Pfizer’s partnership with BioNTech for their COVID-19 vaccine. Mr. Lane joins with more than 20 years of experience in advising life sciences companies, including more than 15 years at Cowen Group, a leading life sciences focused investment bank.

Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences said: “We are excited to welcome Monika and Matt to the team. Their collective expertise in complex deal structuring, and their networks in the biopharmaceutical sector will help us expand our investment activities as we seek to advance important medicines to patients.”

Before joining Blackstone Life Sciences, Dr. Vnuk spent nearly 15 years in leadership roles at Pfizer, including most recently as Vice President of Worldwide Business Development. In that role she led the negotiation of the successful partnership with BioNTech directed at the global co-development and distribution of COVID-19 vaccines. Before joining Pfizer, Dr. Vnuk worked in investment banking at Bank of America and at Oxford Bioscience Partners, a life sciences venture capital firm. Dr. Vnuk holds an MD degree from the Boston University School of Medicine and a B.A. from Boston University.

Prior to joining Blackstone Life Sciences, Mr. Lane was a Managing Director at Gilmartin Group LLC, a strategic advisory firm. Before joining Gilmartin, Mr. Lane spent more than 15 years with Cowen Group as a Managing Director where he focused on supporting life sciences companies at all stages of their development. Before working in finance, Mr. Lane served as Press Secretary to US Senator Judd Gregg. He received a B.A. from Amherst College.

In July 2020, BXLS raised the largest private life sciences fund to date and currently has more than $7 billion in assets under management.

About Blackstone Life Sciences
Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients’ lives. More information is provided at https://www.blackstone.com/our-businesses/life-sciences/.

Contact
Paula Chirhart
+1-347-463-5453
paula.chirhart@blackstone.com

Categories: People

Annabel Arthur joins KKR as Head of EMEA Corporate Communications

KKR

October 1, 2021

Annabel will lead KKR’s strategic communications activities in EMEA across KKR’s investment platforms, managing all external communications, brand-building and content development as well as KKR’s EMEA agency network. She will also provide communications support and advice on external engagement to KKR’s portfolio companies.

 

Annabel was previously Head of Asia-Pacific Corporate Communications at The Carlyle Group, leading the firm’s communications strategy across the region. Annabel built and drove a renewed approach to communications for Carlyle in Asia-Pacific, working in partnership with the firm’s global and local leadership on a proactive programme that supported the firm’s business objectives and activities. Prior to joining Carlyle, she spent ten years working at different European and global communications agencies in London and Hong Kong. She holds an MA from The University of Edinburgh.

 

Ludo Bammens, Managing Director and Head of EMEA Corporate Affairs, and Kristi Huller, Managing Director and Global Head of Corporate Marketing and Communications at KKR, said: “We welcome Annabel to KKR at an exciting time for our EMEA platform which is seeing significant growth across our core investment platforms in this region; Private Equity, Real Estate, Infrastructure and Credit. Effective communication with stakeholders is a critical part of doing business today. Annabel’s expertise and international experience will be invaluable in driving external engagement and supporting our portfolio companies as we continue to scale in EMEA.”

 

Annabel Arthur, Head of EMEA Corporate Communications at KKR, said: “I’m delighted to join KKR and excited by the opportunity of working with one of the world’s leading investors to communicate the strengths of the KKR platform and the benefits it can provide for companies and clients.”

 

Annabel can be reached at annabel.arthur@kkr.com.

 

–ends–

About KKR

KKR is a leading global investment firm that offers alternative asset management and capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of The Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com and on Twitter @KKR_Co.

 

Media Contacts

Alastair Elwen / Sophia Johnston

Finsbury Glover Hering

Telephone: +44 20 7251 3801

Email: kkr@fgh.com

Categories: People